Abstract
Cancer initiation and progression is the result of an accumulation of mutations. Mutations occurring in cancer tissue are termed somatic, whereas mutations in germline DNA may be passed onto subsequent generations and are often termed hereditary. Deleterious germline mutations in key tumor suppressor genes can lead to hereditary cancer syndromes whereby family members carrying the mutation have an increased susceptibility to developing certain tumor phenotypes. Common features of hereditary cancer syndromes include early age of onset, multiple affected generations, rare tumor types, and/or multiple primary malignancies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Shuch B, Vourganti S, Ricketts CJ, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014;32:431–7.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.
Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016;374:135–45.
Linehan WM. Evaluation and screening for hereditary renal cell cancers. Can Urol Assoc J. 2013;7:324–5.
Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20.
Butman JA, Linehan WM, Lonser RR. Neurologic manifestations of von Hippel-Lindau disease. JAMA. 2008;300:1334–42.
Ho TH, Jonasch E. Genetic kidney cancer syndromes. J Natl Compr Cancer Netw. 2014;12:1347–55.
McNeill A, Rattenberry E, Barber R, et al. Genotype-phenotype correlations in VHL exon deletions. Am J Med Genet A. 2009;149A:2147–51.
Lonser RR, Butman JA, Huntoon K, et al. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg. 2014;120:1055–62.
Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15:55–64.
Kondo K, Kim WY, Lechpammer M, et al. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003;1:E83.
Thoma CR, Frew IJ, Hoerner CR, et al. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol. 2007;9:588–95.
Ding X-F, Zhou J, Hu Q-Y, et al. The tumor suppressor pVHL down-regulates never-in-mitosis A-related kinase 8 via hypoxia-inducible factors to maintain cilia in human renal cancer cells. J Biol Chem. 2015;290:1389–94.
Metcalf JL, Bradshaw PS, Komosa M, et al. K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair. Oncogene. 2014;33:1055–65.
Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172:63–5.
Metwalli AR, Linehan WM. Nephron-sparing surgery for multifocal and hereditary renal tumors. Curr Opin Urol. 2014;24:466–73.
Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011;22:2661–6.
Pilie PG, Matin SF, Woodson AH, et al. Pilot study of dovitinib in patients with VHL disease. J Clin Oncol. 2016;34:587.
Jonasch E, Gombos DS, Waguespack SG, et al. Phase II study of pazopanib in patients with von Hippel-Lindau disease. J Clin Oncol. 2017;35:4516.
Fei SS, Mitchell AD, Heskett MB, et al. Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours. Nat Commun. 2016;7:11588.
The .somatic genomic landscape of chromophobe renal cell carcinoma. – PubMed – NCBI. 2018. https://www.ncbi.nlm.nih.gov/pubmed/25155756?dopt=Abstract. Cited 2018 Mar 22.
Shepherd CW, Gomez MR, Lie JT, et al. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66:792–6.
Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817–24.
Tan M-H, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400–7.
Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008;5:357–61.
Schmid GL, Kässner F, Uhlig HH, et al. Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies. Pediatr Res. 2014;75:527–34.
Ricketts CJ, Shuch B, Vocke CD, et al. Succinate Dehydrogenase Kidney Cancer (SDH-RCC): An Aggressive Example of the Warburg Effect in Cancer. J Urol. 2012;188:2063–71. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856891/. Cited 2016 Nov 12
Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73.
Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31:181–6.
Vocke CD, Ricketts CJ, Merino MJ, et al. Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. Genes Chromosomes Cancer. 2017;56:484–92.
Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Familial Cancer. 2014;13:637–44.
Modi PK, Singer EA. Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis. Ann Transl Med. 2016;4:143. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842405/. Cited 2016 Nov 11
Luijten MNH, Basten SG, Claessens T, et al. Birt-Hogg-Dube syndrome is a novel ciliopathy. Hum Mol Genet. 2013;22:4383–97.
Bratslavsky G, Woodford MR, Daneshvar M, et al. Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium: latest scientific and clinical discoveries. Oncotarget. 2016;7:15292–8.
Johannesma PC, van de Beek I, van der Wel JWT, et al. Risk of spontaneous pneumothorax due to air travel and diving in patients with Birt-Hogg-Dubé syndrome. Springerplus. 2016;5:1506.
Yu H, Pak H, Hammond-Martel I, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A. 2014;111:285–90.
Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92:974–80.
Rai K, Pilarski R, Cebulla CM, et al. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89:285–94.
Mandelker D, Zhang L, Kemel Y, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017;318:825–35.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jonasch, E., Pilie, P.G. (2019). Hereditary Renal Cell Carcinomas. In: Malouf, G., Tannir, N. (eds) Rare Kidney Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-96989-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-96989-3_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-96988-6
Online ISBN: 978-3-319-96989-3
eBook Packages: MedicineMedicine (R0)